GLOBALIZATION, PATENTS AND DRUGS

AN ANNOTATED BIBLIOGRAPHY

Health Economics and Drugs
EDM Series No. 9
Globalization, patents and drugs

An annotated bibliography

Health Economics and Drugs
EDM Series No. 9

Pascale Boulet
Germán Velásquez

Essential Drugs and Medicines Policy
Acknowledgements

The authors would like to acknowledge the following individuals for their comments and suggestions: Professor C.M. Correa (University of Buenos Aires, Argentina), Mr A. Otten (World Trade Organization), Mr R. Wilder (World Intellectual Property Organization), Ms S. Zarrilli (United Nations Conference on Trade and Development).
Table of contents

Abbreviations and acronyms ............................................................................................................ 2
Introduction ....................................................................................................................................... 3
1. General articles ........................................................................................................................... 5
2. Country studies by region ............................................................................................................ 23
   2.1 Africa ...................................................................................................................................... 23
   2.2 Asia ......................................................................................................................................... 24
   2.3 Europe ................................................................................................................................... 30
   2.4 Latin America ....................................................................................................................... 32
   2.5 Middle East ............................................................................................................................ 35
   2.6 North America ....................................................................................................................... 36
3. Electronic information .................................................................................................................... 39
   3.1 Some useful web sites .............................................................................................................. 39
   3.2 Interesting discussion groups ................................................................................................. 40
## Abbreviations and acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>Consumer Project on Technology</td>
</tr>
<tr>
<td>ECJ</td>
<td>European Court of Justice</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GATT</td>
<td>General Agreement on Tariffs and Trade</td>
</tr>
<tr>
<td>HAI</td>
<td>Health Action International</td>
</tr>
<tr>
<td>IFPMA</td>
<td>International Federation of Pharmaceutical Manufacturers Associations</td>
</tr>
<tr>
<td>IPP</td>
<td>intellectual property protection</td>
</tr>
<tr>
<td>IPRs</td>
<td>intellectual property rights</td>
</tr>
<tr>
<td>NAFTA</td>
<td>North American Free Trade Agreement</td>
</tr>
<tr>
<td>NGO</td>
<td>nongovernmental organization</td>
</tr>
<tr>
<td>NOC</td>
<td>notice of compliance</td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Co-operation and Development</td>
</tr>
<tr>
<td>OTC</td>
<td>over-the-counter (drug)</td>
</tr>
<tr>
<td>PCT</td>
<td>Patent Cooperation Treaty</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>research and development</td>
</tr>
<tr>
<td>S&amp;T</td>
<td>science and technology</td>
</tr>
<tr>
<td>SEARO</td>
<td>WHO Regional Office for South-East Asia</td>
</tr>
<tr>
<td>TRIPS</td>
<td>Agreement on Trade-Related Aspects of Intellectual Property Rights</td>
</tr>
<tr>
<td>TWN</td>
<td>Third World Network</td>
</tr>
<tr>
<td>UNCTAD</td>
<td>United Nations Conference on Trade and Development</td>
</tr>
<tr>
<td>UPOV</td>
<td>International Union for the Protection of New Varieties of Plants</td>
</tr>
<tr>
<td>WCC</td>
<td>World Council of Churches</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WIPO</td>
<td>World Intellectual Property Organization</td>
</tr>
<tr>
<td>WTO</td>
<td>World Trade Organization</td>
</tr>
</tbody>
</table>
Introduction

Many WHO Member States have expressed concern about the effects of the TRIPS Agreement on access to pharmaceuticals, and in May 1999 the World Health Assembly mandated WHO “to cooperate with Member States, at their request and with international organizations in monitoring and analysing the pharmaceutical and public health implications of relevant international agreements, including trade agreements.”1

The TRIPS Agreement is one of the most controversial of the Uruguay Round in terms of content, objectives and possible consequences. This is clearly shown by the entries in this bibliography, in which some authors argue that patent protection of pharmaceuticals will lead to:

- an increase in the flow of technology transfer and foreign direct investment to the benefit of developing countries;

- an increase in the resources devoted to R&D of needed new drugs, ensuring a dynamic pharmaceutical industry;

- the end of the “brain drain” from developing to industrialized countries, caused by the absence of patent protection in developing countries.

However, other authors assert that:

- the price of patented drugs will increase with the strengthening and prolongation of the patent holders’ monopoly;

- pharmaceutical production will increasingly be concentrated in industrialized countries and it will be difficult for local manufacturers in developing countries to survive;

- the introduction of patents for pharmaceutical products will certainly not lead to an increase in R&D investment in developing countries.

This annotated bibliography aims to inform people in the health sector, with no particular legal background, about the impact of globalization and trade agreements on access to drugs, and the growing importance of this issue. It directs the reader to key reports, books and articles from technical and scientific journals, both general references and specific country studies. Details of some useful web sites are also given.

Some provisions of the TRIPS Agreement (such as the scope of patent protection, compulsory licences and exceptions to patent rights) permit a range of interpretations as to how they are implemented in national laws. These provisions will be interpreted within WTO. However, WHO will help countries

1 Resolution WHA52.19(7).
to interpret and implement TRIPS and other international trade agreements with public health implications. WHO's mandate, as the UN technical agency promoting public health, is to intervene when health interests are affected by globalization and to propose measures to protect these interests. It is hoped that the bibliography will help countries to make the most appropriate decisions relating to new international trade agreements, bearing in mind that access to essential drugs is a fundamental human right.
1. General articles


This report approaches the exhaustion/parallel imports question in broad economic terms, asking whether there may be an economic and social welfare benefit to permitting IPRs holders to block parallel imports that outweighs the potential harm to liberalized trade. It addresses each major form of IPR separately and concludes with respect to each form that the evidence of benefits that might flow from allowing parallel imports to be blocked is insufficient to justify the potential inhibition of trade. The report observes that most objectives that IPRs holders seek to achieve by the allocation of geographical markets can be attained through less trade-restrictive means, namely through the vertical allocation of distribution territories by contract. The interests of the developing countries are a focus of the report, which concludes that developing and developed countries are better served by open markets and the operation of comparative advantage. The report recommends that the WTO adopt a rule precluding governments from blocking parallel imports save in certain exceptional cases.


In this paper, the case is laid out for restricting parallel trade in products protected by IPRs, and pharmaceuticals in particular. The paper responds to three arguments made in favour of open parallel trade. First, it is argued that in the case of patented products with high fixed costs, such as pharmaceuticals, parallel trade may decrease global economic welfare. Attention is drawn to price controls within the EU Member States as a distortion which is inconsistent with open markets principles. Second, it is suggested that rules restricting parallel trade are a necessary corollary to pharmaceutical price discrimination in favour of developing countries. Finally, the paper indicates that restrictions on parallel trade in the pharmaceutical sector are necessary to protect the public against risks arising from inadequate supervision of the secondary market, such as risks from inappropriate repackaging and inadequate storage and handling procedures, and counterfeit products.


This paper discusses briefly the major issues with respect to developing countries. The author insists on how pharmaceutical innovation is dependent on patent protection, and on the benefits for the local industry and consumers, in terms of prices and of new drugs put on the market. Finally, the author regrets
that the TRIPS transition provisions allow such countries as Argentina, India and
the Republic of Korea "an unfortunate grace period, allowing them to exploit
consumers".

Braverman M, Holsomback T. Patent and trademark infringement involving generic
drugs and medical devices – the potential liability impact on pharmacists. Journal of

The use of generic formularies, medical devices and unit-dose packaging often
presents hospital pharmacies with potential infringement liability. In the US,
pharmacists can be held liable for patent infringement if they participate in
"making, using, selling" an unpatented copy of a brand name or medication or a
medical device already protected by a patent. Selected patent and trademark
infringements are discussed with regard to their impact on the practice of
pharmacy. A variety of legal cases are cited and used as examples to evaluate
the impact of patent and trademark infringement on hospital pharmacists in
particular.

Challu PM. The consequences of pharmaceutical product patenting. World

This study presents the results of research based on historical statistical series.
The results shed light on the various effects of a patent system. The first part
analyses the benefits attributed to patenting pharmaceutical products and shows
that patent protection is rather a reflection of the degree of economic
development that a country has already achieved. The second part assesses the
welfare loss experienced by consumers due to monopoly prices of patented
drugs, and also the public cost, or the amount that must be spent by the public
sector to maintain pharmaceutical consumption at a level equal to what would
occur in a fully competitive market. Finally, the study evaluates the costs that
would be imposed on Argentina in order to adopt a product patent system.

Challu PM. Adaptation of national legislation to TRIPS Agreements of GATT's
Uruguay Round, aimed at assuring inhabitants best accessibility to pharmaceuticals.

The TRIPS Agreement sets out with precision some of the obligations
undertaken by WTO Members, while other obligations are subject to diverse
interpretation frames and degrees of freedom. This opens up the possibility of
analysing the best way to draw up laws that the countries must enact to fulfil the
commitments undertaken in the Uruguay Round, so that they comply with the
requirements of health and social policies. The author outlines the balance of
objectives and interests within the TRIPS Agreement, which can be found in the
preamble and general principles. This balance makes it possible to establish
local rules that take into account the need to guarantee people the best possible
access to drugs. The article therefore analyses the potentialities in the
Agreement to minimize the monopoly conferred by a patent in order to improve
the supply of and access to pharmaceutical products: exceptions to exclusive
rights, supply increase through importation, compulsory licences, reaction to anti-competitive practices in licence contracts, and transitional periods.


The TRIPS Agreement is perhaps the most far-reaching international instrument ever adopted on IPRs. This article analyses the main provisions of the TRIPS Agreement in the area of patents. Its purpose is to provide a preliminary interpretation of the most relevant aspects of the text, namely new patentable fields of technology, criteria of patentability, the non-discrimination clause, rights conferred and exceptions, conditions for patent applications, compulsory licensing, reversal of the burden of proof, and transitional arrangements.


This paper discusses the relationship between foreign direct investment and intellectual property rights. It aims to provide an analytical framework with which to understand this relationship and to deal with it. The multiple variables that affect the relationship, the industries involved and the degree of development of countries are considered first. The main developments that have recently taken place in national legislations and within WIPO, UPOV and GATT are outlined with regard to strategies and decisions for foreign direct investment. An analytical framework is then presented and the significant differences it exposes when applied to different types of intellectual property are exemplified by case studies.


The aim of this study is to examine the possible effects of the TRIPS Agreement on the development, production and marketing of drugs, as well as access to them. The author reviews the areas of intellectual property which are the most relevant to the pharmaceutical sector, namely patents and "confidential information" (trade secret). The provisions on transitional periods and on the mechanism for the settlement of disputes are also analysed. The last part of the study reviews the possible implications of the Agreement for innovation, foreign direct investment and the price of drugs. The analysis focuses on the effect of the new intellectual property rules in developing countries.


This is a background paper on the TRIPS Agreement that presents the context of and reasons for its negotiation, the issues at stake, and the North and South
asymmetries with regard to IPRs. The paper presents the main provisions of the Agreement regarding all kinds of IPRs and concludes by discussing the implications for developing countries.


The adoption of the TRIPS Agreement in 1994 was a historic change in intellectual property, with profound implications in the area of pharmaceuticals. This paper therefore considers the developments that have taken place in that field since the entry into force of the Agreement in January 1995. Without prejudice to the significance of these developments, it seems clear that it is in developing countries that the patenting of pharmaceuticals has undergone dramatic changes. This paper considers a number of issues that have arisen in countries which have recently introduced pharmaceutical product patents or are applying the transitional period, namely exclusions from patentability, patents on formulations and therapeutical uses, exceptions to exclusive rights ("Bolar" exception, experimental use, parallel imports), compulsory licensing, exclusive marketing rights, etc.


This article shows that with respect to the specific area of patents the TRIPS Agreement does not constitute a uniform law. It provides a number of minimum standards that will substantially increase the degree of harmonization in IPP, but it leaves considerable scope for national laws to define a number of important aspects. The room for manoeuvre left by the Agreement derives, in some cases, from the wording of its provisions, such as Articles 30 and 31, and in other cases from the absence of any specific rule. The author argues that developing countries can opt for a number of approaches aimed at fostering access to technology and promotion of innovation at national level in a way that is fully consistent with the TRIPS Agreement.


This paper examines the WTO TRIPS Agreement and tries to analyse those areas in which the Agreement will impact, either positively or negatively, on sustainable development in developing countries. After brief introductions to the Agreement itself, and to the concept of IPRs, the paper turns to examining the possible effects of the Agreement, focusing on agriculture and biodiversity, pharmaceuticals and copyrighted goods. It ends by proposing a number of policy actions which contribute to sustainable development in the context of the Agreement.

This paper provides an analysis of the challenges to the pharmaceutical industry such as the increase in R&D costs and competition from generic manufacturers. It also studies the implications of the Uruguay Round Agreements for the local pharmaceutical industry, in particular the TRIPS Agreement and its consequences in Argentina, Brazil, India and the United States.


The main debate with regard to the impact of the TRIPS Agreement on public health in developing countries relates to the potential increase in drug prices. On the basis of a study by Rozeq and Bercowitz (1998), IFPMA affirms strongly that patents do not have any negative effect on drug prices. However, the main reason for including the TRIPS Agreement in the Uruguay Round agenda was the extraordinary losses of the innovative pharmaceutical industry due to non-patent protection in some developing countries. A number of economic studies have tried to measure the increase in the price of drugs if pharmaceutical patent protection is included in the patent law. All conclude that prices will increase. The question is how much. This paper reviews most of these studies on the basis of three different approaches: theoretical model of prices, comparison between the prices of patented drugs and drugs out of patent, and the drug situation in countries which have recently introduced patent protection.


This article discusses proposed legislation in Canada ordering cigarette companies to use plain packaging as a public health measure. This proposal triggered off a threat by United States trade officials, who argued that it was a violation of international trade agreements.


This document contains a brief description of the GATT and the WTO, their history and development, and the main provisions of the new trade agreements. The position of the consumers' movement is presented, emphasizing the influence of the pharmaceutical industry lobbies in the establishment of development costs of pharmaceutical products. WHO's view on the Agreement on Technical Barriers to Trade and the TRIPS Agreement is set out. There is a description of the work of the WTO and its position in the pharmaceutical field. Finally, an NGO's view is presented, stressing the unjustified advantage that the TRIPS Agreement gives to multinational corporations at the expense of developing countries and of public health.

The courts in two industrialized countries, England and Japan, have recently confirmed the lawfulness of parallel importation of patented products in the absence of any indication to the contrary. Continental law follows a different philosophy and assumes absolute limits of intellectual property rights within the principle of exhaustion of rights. However, applying the principle of international exhaustion has sometimes been objected to by invoking the principle of "territoriality of patents" of the Paris Convention. The author analyses the parallel import provision of the WTO TRIPS Agreement which, he recalls, is meant to remove trade barriers and to ensure a balance of rights and obligations. However, the author argues for harmonization on this matter as a conclusion.


The Uruguay Round deals that were finalized in 1994 include the little known (at that time) general agreement on TRIPS. While representatives of big companies were sitting at the drafting table, little account was taken of the consequences of increased prices for medicines in the South. A preliminary assessment points to a negative outcome.


This publication presents the view of the International Federation of Pharmaceutical Manufacturers Associations on the TRIPS Agreement. It covers developments concerned with the general provisions, the rules relating to patents, the means of ensuring respect for intellectual property rights, the settlement of disputes and the transitional provisions.


This publication sets out to discuss many of the issues raised in discussions of patent issues. According to the authors, pharmaceutical patent protection brings a number of economic benefits: it is an indispensable element of economic development and growth; it encourages local inventors to disclose and commercialize their inventions; it improves a country's credibility and recognition as a dependable supplier; and it is an essential element in the provision of more cost-effective health care. Moreover, strong intellectual property protection is particularly important for pharmaceutical products, owing to their unique characteristics. The paper then discusses the "reality" of patent protection for pharmaceuticals in response to the fears and doubts expressed with regard to monopolistic price increases, foreign direct investment and the demise of the local pharmaceutical industry. Finally, an entire chapter is
dedicated to the "long, expensive and painstaking journey" involved in the development of a new drug.


The Indian pharmaceutical industry made excellent progress within the framework of the 1970 patent law, as is evident from process research and production data. This paper deals extensively with the comparative analysis of the existing and the new patent system and the safeguards which have to be provided in the public interest to accomplish the goals of "health for all". The first part introduces the basic elements of the patent system and its history. The second part offers a picture of the global and of the Indian pharmaceutical market. Then, after a very detailed presentation of the framework of the TRIPS Agreement, the author demonstrates that this Agreement is indeed an extreme compromise of public interest and assesses what may be the impact on the availability of pharmaceutical products. He concludes with recommendations on the approach developing countries should adopt.


The WTO Agreement on Technical Barriers to Trade is designed specifically to encourage application to traded goods of internationally agreed standards, including WHO's quality standards for pharmaceutical, biological and food products. The Agreement on Sanitary and Phytosanitary Measures sets out to harmonize national measures to protect human, animal and plant life or health, stipulating application of the food quality standards drawn up by the WHO/FAO Codex Alimentarius Commission. By virtue of the General Agreement on Trade in Services, Members may open up their domestic market to foreign suppliers of hospital and medical services; and the TRIPS Agreement raises concerns about the continued accessibility of adequate drug supplies at reasonable cost in developing countries. Public health personnel may not always be provided with adequate information on an area that is not directly related to their work. With this in mind, this paper reviews the several agreements within the Final Act of the GATT Uruguay Round, which have implications for WHO's work, outlining their purpose, main provisions and obligations, with particular reference to developing countries. In each case, information is given on the WHO activity involved, pinpointing what is already being done to protect health, and, in some cases, how public health work can facilitate trade relations.


The pharmaceutical industry claims that patent protection of inventions is crucial and that healthcare innovation is indeed totally dependent on patents. This article considers why pharmaceutical R&D relies so much on patents, what constitutes effective patent protection for that industry and how the patent system might develop in the future, particularly in Europe.

Globalization puts pressure on governments’ abilities to regulate taxes on wealth and labour, and on cultural and environmental as well as public health standards. Who will benefit from these new agreements? The need for a social clause campaign is growing.


J. Mackay is the executive director of the Asian Consultancy on Tobacco Control, a coordinating organization to facilitate sharing of information, experience and expertise on tobacco control among countries in the Asia-Pacific region. W. Zatonski is the head of the department of epidemiology and cancer prevention at the Marie Curie Memorial Cancer Center and Institute of Oncology in Warsaw, Poland. H. Chitanondh is the president of the Thailand Health Promotion Institute of the National Health Foundation, as well as president of the Asian Pacific Association for Control of Tobacco. E. Le Gresley is legal counsel to the Non-Smokers Rights Association, the leading Canadian anti-tobacco industry advocacy group.


All inventors and manufacturers of new pharmaceutical products want to be able to maintain their exclusive right to exploit the invention by protecting it with a patent. However, manufacturers protest that they are unable to exploit the patent until they have obtained marketing authorization, and that therefore effective patent protection is reduced to eight or nine years. This article examines three ways in which companies can apply European and national law to breathe commercial life into a product beyond the patent term: patent term extension through Supplementary Protection Certificates, marketing exclusivity, and OTC switches.


This paper focuses on concerns raised about the additional market power created by stronger property rights in technology and information. It sets out the basic theory of fundamental trade-offs posed by IPRs in open economies. The limited evidence available on potential price impacts of stronger protection is reviewed in three key areas: pharmaceuticals, plant varieties and software. The paper also considers the role of IPRs in supporting restrictive conditions in licensing contracts. Finally, it discusses aspects of competition policy that might be used to ensure that stronger IPRs promote dynamic competition rather than foster competitive abuses.

The rapidly growing number of disease gene patents – patents that claim all methods for diagnosis of a particular genetic condition – threaten the ability of physicians to provide medical care to their patients. This article discusses some of the ramifications of creating a monopoly over a medical service, assesses the implications of disease gene patents for clinical laboratories, and proposes some strategies for responding to this new phenomenon. The analysis concludes with a recommendation that the patent law be amended to require compulsory licensing of medical process patents. Indeed, according to the author, "it is time to evaluate the need for such a provision for medical process patents in light of the serious harm to the practice of medicine, and arguably, to the public health, that may result from a refusal to license".


This article discusses the unique situation of drug patents with reference to R&D costs and FDA testing. It critiques the aftermath of patent term extension under the US Hatch-Waxman Act and the economic behaviour of pharmaceutical manufacturers, with a focus on life-saving drugs and the AIDS crisis. The author reminds readers that the consumer was meant to be the real winner of this reform and concludes that "maybe patenting is not a good idea in the area of life-saving pharmaceuticals".


During recent years, case law in Europe has quite frequently dealt with the interpretation of the exclusion of medical methods from patentability. This article first presents the historic roots and development of the exclusion of medical methods, from national developments to European patent law harmonization. It then examines in detail the scope and limitations of the prohibition on patenting of surgical, therapeutic and diagnostic methods.


All OECD countries surveyed have a standard 'baseline' harmonization of patent law, largely as a result of implementation of the obligations set out in the TRIPS Agreement. EU Member States have achieved additional harmonization of extended patent term legislation. More significant variations exist between EU Member States and other OECD jurisdictions, as well as between the non-EU OECD States, as regards the scope and operation of permitted exceptions to exclusive patent rights, where different balances have been struck between the interests of patentees and the promotion of effective generic competition. Important differences also exist between European Patent Convention
Contracting States and other OECD countries in respect of the scope of patentability of second medical uses for known drug substances, or the linking of grant of marketing authorizations to non-infringement of the patent rights of the original patentee. Finally, the report does not find a significant bearing of compulsory licensing and issues of exhaustion of IPRs on the development of the generic industry.


This article offers a discussion on the question of why there are pressures on developing countries for introducing and/or reinforcing patent protection for pharmaceutical drugs. It first reviews the worldwide pattern of patent policies and the pressures from industrial countries on developing countries for modification of patent laws relating to pharmaceutical drugs in particular. It then presents evidence on the relative importance of patents for the pharmaceutical industry. It discusses changes in effective patent duration as modified by regulatory policies. It finally presents evidence on the growing importance of competition between brand names and the generic drug industry, and the impact of this competition on drug prices. The potential size of developing countries’ markets for patented drugs is no longer trivial.


In the Uruguay Round, industrial countries proposed that developing countries extend patent protection to pharmaceutical drugs. By looking at the pharmaceutical industry, this paper argues that neither side has a strong case in its favour and that more research is needed before an economically sound decision is made. The paper starts by offering a political economy discussion of why industrial countries have reached a consensus in favour of introducing patent protection for pharmaceutical drugs. The central point of the paper is then supported by further analysis that discusses the social costs and benefits of introducing patent protection for pharmaceutical drugs in developing countries.


The protection of pharmaceutical inventions was one of the key issues in the Uruguay Round negotiations as a whole and perhaps the key issue in the North-South axis of negotiations. It was the last issue to be resolved. At that time, it was clear that there would be no TRIPS Agreement without a commitment to make available patent protection for pharmaceuticals for 20 years. The question therefore was: on what terms would countries’ delegations accept such an obligation, in particular in regard to such matters as the exhaustion of rights, compulsory licensing, the control of anti-competitive practices, test data
protection and transitional arrangements? The paper takes up each of these aspects.


While drugs offer a simple, cost-effective solution to many health problems, effective treatment is lacking in poor countries for many diseases. This article focuses on the problems of access to quality drugs for the treatment of diseases that predominantly affect the developing world. Poor-quality and counterfeit drugs are not rare in developing countries. Fluctuating production or prohibitive costs also account for the lack of availability of essential drugs. The development of field-based drug research is needed to determine optimum utilization and re-motivate research and development for new drugs for the developing world. Potential consequences for the availability of old and new drugs are expected from recent World Trade Organization agreements.


This paper discusses the international dimension of intellectual property protection, with an emphasis on the implications for developing countries. It explores the effects of IPRs protection on trade, foreign direct investment and technology licensing, and reviews empirical evidence in this context. Finally, it discusses how international transactions in intellectual property affect the international transfer of knowledge.


This book is an effort to place in the hands of the Third World public, and concerned groups, information on the Uruguay Round and its implications. It is not intended to be an academic or objective exercise, but has been written from a Third World perspective and is aimed at filling the gap in other publications. Part one deals with the political economy of the Uruguay Round and its broad implications in terms of South-North relations. Part two deals with the new themes on the agenda of the Round and their interlinkages. Part three looks at some of the traditional and old issues of trade and market access, particularly those of importance to the Third World countries. In the light of these, Part four looks at issues with systemic implications. Part five deals with the progress in the negotiating processes in the first two years and the outlook in the light of the mid-term review. The book also updates the situation up to 1990 and presents some views on what positions the Third World countries should take.
**Reichman JH. Universal minimum standards of intellectual property protection under the TRIPS component of the WTO Agreement. International Lawyer, 1995, 29(2):345-388.**

According to the author, "the absorption of classical intellectual property law into international economic law will gradually establish universal minimum standards governing the relations between innovators and second comers in an integrated world market". This article provides a detailed and comprehensive picture of all the important substantive provisions contained in the TRIPS Agreement, including patents, trademarks and the ongoing trade-based initiatives, such as the compensation expected by developing countries and the uncertainties of the dispute-settlement process. A section specifically discusses the issue of compulsory licences and the new dimension of the public interest exception under the TRIPS Agreement.

**Reichman JH. From free riders to fair followers: global competition under the TRIPS Agreement. New York University Journal of International Law and Politics, 1997, 29(1-2):12-93.**

The article identifies the sources of tension between developed and developing countries, and evaluates the impact of the TRIPS Agreement on developing countries' capacity to acquire the knowledge and skills they need to compete on the market of technological goods. It argues that developing countries have much to gain by accepting the challenge implicit in the Agreement to become fair followers in the worldwide quest for technical innovation. The author outlines a pro-competitive strategy for implementing the TRIPS Agreement in developing countries in five points: tilt their intellectual property laws in favour of local competitors; distance themselves from protectionist measures being adopted in the developed countries; institute incentives structures to stimulate innovation at the local level; resist any further elevation of international intellectual property standards beyond the TRIPS; and resort to the global information infrastructure to acquire scientific and technical knowledge.


The TRIPS Agreement is indeed a major event in the history of intellectual property law. This study examines the impact of this Agreement on patent law in the pharmaceutical sector in developing countries. It suggests reconsideration of the sensitive issue of the balance of interests that the patent system is designed to ensure. It analyses the various provisions of the TRIPS Agreement that leave a certain margin of freedom to Member States in the organization of the patent system. The application of general principles, together with respect for conditions for the limitation of patent rights, allows a number of measures that may take into consideration national development and public health needs.

According to the author, the article of Pablo Challu on the consequences of pharmaceutical product patenting "is fatally flawed in its conceptual and empirical analysis". The most severe shortcomings of his article are a misunderstanding of the causes of economic modernization, inaccurate or incomplete data, and inappropriate price comparisons. The author concludes that protecting intellectual property should be a "public policy goal of developing countries seeking sustained economic growth".


The authors studied prices of pharmaceutical products in nine developing countries with and without patent protection over a period of 11 years to determine whether enacting intellectual property law increases the price of drugs. Their conclusion is that escalating prices seem unlikely for a number of reasons: therapeutic competition among many pharmaceutical products, monopsony buyers and price-regulation schemes for pharmaceuticals in developing countries, and the fact that new intellectual property laws usually do not apply to existing products.


Problems arise when a drug is already known for one or more therapeutic applications and another, hitherto unknown, curative or preventive property of that drug is subsequently discovered. This article addresses the legal difficulties raised by the patentability of the second therapeutic application with regard to the novelty and the industrial application of such an invention.


The expectation of profit is the principal lure leading pharmaceutical companies to invest large sums for the discovery and development of new drugs. Companies hope to develop products sufficiently important to repay or more than repay their R&D investments. Patent protection on marketed new chemical entities is a significant complement to their profit-earning expectations. This paper evaluates the role that patent protection plays in pharmaceutical R&D, and analyses some policy implications with special emphasis on developing nations.

"The TRIPS Agreement meets the objectives that the United States established for the negotiation", says the author. This Agreement sets forth minimum standards for the protection of IPRs and provides for effective enforcement of these rights internally and at the border. An enhanced dispute settlement regime is also available to address shortcomings in meeting TRIPS obligations. Obligations have to be met by all countries, within the transitional arrangements.


This document forms part of the programme of work carried out by the South Centre as a contribution to the Economic Agenda for Priority Action 1992-1995 of the Non-Aligned Movement. The document is intended as an introductory overview of the TRIPS Agreement for developing countries. In addition to highlighting some of the central issues for the South, the document draws attention to the aspects to which policy-makers and technical personnel should pay special attention when formulating policy and legislation in this field. In particular, the document points out that "maximum advantage must be taken of those areas where the Agreement leaves some room for choice in an effort to ensure that national policies and legislation are formulated in a manner that helps to achieve their development objectives". Also, it is suggested that there are a number of areas in which developing countries could cooperate to great mutual advantage, with respect both to the formulation of national implementing legislation and to the planned review of the Agreement.


This paper estimates the changes in prices, profits and social welfare arising from increased patent protection of pharmaceuticals in a number of developing countries. Two market structures are proposed (perfectly competitive market and Nash-Cournot duopoly) and comparisons are made between the situation where there is no patent protection and after the introduction of patent protection. Lags between the adoption of legislation and its impact are discussed and the effects of retroactive legislation compared with non-retroactive patenting. Prices of patented drugs in three countries (Argentina, India and Malaysia) are then compared and possible price changes discussed. Finally, for larger countries, or a group of small countries, the effects of patent protection are calculated for the same scenarios and the incentives for increased research and development are examined. The paper concludes that the effects of patent protection are sensitive to assumptions about market structure and price elasticity.

This report on the pharmaceutical industry will be published in two parts. The first part provides an overview of the characteristics of the industry and current trends in its growth and structure: production and consumption, employment, research and development, capital investment, firm and product concentration and product competition, and pricing. A discussion follows on international trade covering intra- and interregional, intra-firm and intra-industry trade. The second part will look at foreign direct investment, inter-firm networks and governmental policies.


According to the author, "Fundamental shifts in technology and in the economic landscape are rapidly making the current system of intellectual property rights unworkable and ineffective. Designed more than 100 years ago to meet the simpler needs of an industrial era, it is an undifferentiated, one-fits-all system". Four main reasons explain the problems with the old system: the centrality of intellectual property rights, the decline of public knowledge, the emergence of new technologies and the globalization of the economy. Thus, a new system of IPRs should strike the right balance between the production and the distribution of new ideas, but should also be really enforceable, quick and efficient. A revised system should reflect diverse interests, such as public versus private knowledge, developed versus developing countries, and different types of industry, knowledge and inventors.


The expert group was convened by TWN with the objective of bringing together a team of individuals with in-depth knowledge of IPRs in order to provide guidelines and proposals to policy-makers and the public in developing countries on the options available to them during the process of implementing the TRIPS Agreement. The TRIPS Agreement had been actively promoted by industrialized countries with the aim of obtaining worldwide protection for the innovations and technologies generated by their corporations. The implementation of the Agreement could have some serious adverse consequences for developing countries, including placing greater obstacles in the way of their technological development. This report points out the options available in various aspects of the TRIPS Agreement, and proposes recommendations on options which would be more appropriate to and consistent with the interests of developing countries. The report focuses on the provisions related to patents, undisclosed information, computer programs and restrictive practices in contractual licences.

This report provides an initial assessment of the costs of implementing and enforcing the specific intellectual property rights standards stipulated in the TRIPS Agreement. A preliminary section sets out for the main findings and conclusions, the key issues, and the role that international organizations can play in assisting developing countries in their efforts to implement the TRIPS Agreement. Part one assesses the economic implications of the Agreement for developing countries, focusing on market-related costs and benefits, as well as the direct costs stemming from the implementation of the TRIPS Agreement. It also summarizes the results of selected country case studies carried out for the purpose of this study. Part two deals with the main disciplines covered by the TRIPS Agreement. It highlights the principal provisions of each of the disciplines discussed, its main economic and legal implications, general issues arising from its implementation and the costs involved in implementing it. Finally, an annex provides an overview of the literature on the impact of introducing pharmaceutical product patents.

Available from: URL: http://www.who.int/dap/Pagespublications/Economicspub.htm

The new international economic and social context is likely to have an important effect on the equitable access of populations to health and to drugs, especially in developing countries. The new rules in the area of intellectual property could increase these countries’ dependence still further. In implementing the TRIPS provisions at the national level, developing countries should be aware that there are some options for ensuring access to essential drugs for the poorest populations, as some provisions of the TRIPS Agreement may be used to protect public health goals. Therefore, say the authors, each country’s strategy in regard to globalization in the field of the production and distribution of drugs will have to be incorporated into its national pharmaceutical policy, a component of national health policy.


The operation of the new intellectual property regime has yet to be seen, but given the fact of intense negotiations which accompanied its adoption, a few pertinent questions may be asked about the efficacy of the new regime for developing countries. Patenting in pharmaceuticals is still open to considerable debate in most developing countries. Will the emerging new regime work in the national interest of the developing countries? Will it encourage the transfer of technology to them from developed countries and help them become competitive in world trade? Will it help in boosting the inventive and innovative capacity in these countries? These are some of the issues addressed in this article, which for this purpose explores at the outset relevant provisions of the TRIPS Agreement.

By bringing IPRs within the context of the GATT/WTO, the exclusivity aspect of IPRs has been made subject to the rules of international trade and competition. This study examines the issue of IPR exhaustion in the GATT/TRIPS context, and tries to analyse whether territorial exhaustion fits into the GATT stated objective of free trade, its legality under the GATT/WTO provisions, and its effects on developing countries. The author argues for world-wide rather than territorial exhaustion, for the sake of free trade and international competition. In this context, the study first briefly discusses the concept of IPR exhaustion and current practice thereon, as exhibited in the legal systems of Japan, the EU and the US. That is followed by an analysis of the legal and economic commitments to international exhaustion within the GATT/WTO framework. Finally, the issue is examined from the point of view of developing countries.


With the debate on cloning still ringing in one’s ears, it was not entirely unexpected that Dolly, the cloned sheep, is the basis of a patent application. This article addresses the problems of applying a morality criterion through the patent system and looks to both the Oncomouse case and the impending patent application on cloning in order to consider whether the morality of patenting is being addressed on a realistic basis.


According to the report, "The meeting at WCC established that the protectionism promoted by this Agreement works against the interests of developing countries". Speakers at the meeting included Professor Carlos Correa (Argentina), Dr Mira Shiva (India) and Dr Zafar Mirza (Pakistan), and representatives from WHO and WTO. The report provides speakers’ presentations, which include a background to the issues raised by the TRIPS Agreement, the effect of TRIPS on local manufacturing, and concerns about justice following the TRIPS Agreement


Intellectual property protection has become a central part of the free trade agenda and of the global WTO agreements. This article considers how this state of affairs came to be and what it means for developing countries. Its crucial concern is with the range of pharmaceutical patent policy options that remain open to them. Part I provides some background on the range of possible patent regimes, to emphasize that there is no single approach to patent policy. Part II
recounts the United States pharmaceutical industry’s political offensive over the last 15 years, designed to ensure that all nations adopt restrictive patent laws. Part III undertakes a close analysis of the TRIPS Agreement and argues that despite its appearing highly restrictive at first glance, the Agreement leaves in fact a number of options open to developing countries. Part IV considers the costs and benefits of some patent policy alternatives, especially compulsory licensing, and, in a concluding section, outlines a patent policy approach for developing countries that would better serve their national interests.
2. Country studies by region

2.1 Africa


Controversial reforms to reduce drug prices in South Africa have angered the pharmaceutical industry and led to the country being threatened with sanctions by the US. The author relates the history of the Medicines Amendment Act culminating in court action. She then examines what she sees as the faults of the proposed legislation with a close look at section 15C, the main source of controversy, and the threat of parallel imports and compulsory licensing.


The main features of this South African legislation would facilitate aggressive marketplace competition for pharmaceutical drugs, through encouraging the use of generic drugs and parallel imports. This paper provides discussions on the issues of parallel imports: their nature, scope, use in other countries and their status in the TRIPS Agreement. The issue of health registration data in South Africa is also discussed.


The South African Government has drawn up a series of measures, including a National Drug Policy, to reform the country’s healthcare system. In this issue, Dr Ian Roberts explains the reasoning behind the proposals and what it is hoped they will achieve, while Mirryena Deeb puts forward industry’s reaction to the draft legislation.


This paper examines the state of intellectual property rights and their protection and exploitation in African countries. Listed are the coverage of intellectual property laws, the subject matter of protection and the scope of rights conferred. It is shown that African legislation is generally comparable to that in developed countries with regard to terms of protection, compulsory licensing, subject matter and government and public interest use. A comparison is made between
developed countries and African members of GATT in regard to fields excluded from protection. The results of surveys of some individual African countries reveal the extent of registration of patents and technology transfer to these countries. Finally, the possible impact of new legislation, especially in the context of the TRIPS negotiations of the Uruguay Round, is considered.

2.2 Asia


This article from an Indian firm describes the discussions in India between Indian firms, the Government and the multinational drug industry on the issue of pharmaceutical patents and TRIPS. The author analyses the shortcomings of the 1970 Indian Patent Act vis-a-vis the TRIPS Agreement and the amendments necessary for compliance with the TRIPS provisions. He then presents the status of pharmaceutical patents in the pre-GATT era and discusses the post-GATT implications, including the future for R&D.


The last decade has witnessed a virtual revolution in the protection and enforcement of IPRs in the Asia Pacific region. Almost every single country in the region has either replaced or substantially renewed its intellectual property laws. Counterfeiting and piracy in Asia were perceived as a damaging issue in international trade. The author notes that the special 301 Section of the United States Trade Act has been intensively used in the region to support the views of the United States at the Uruguay Round negotiations and the adoption of the TRIPS Agreement. This article describes the various developments and law reviews that have occurred in each country of the region, as well as on a regional basis.

Debroy B. Beyond the Uruguay Round: the Indian perspective on GATT. New Delhi, Response Books, 1996.

This book looks beyond the Uruguay Round and is an Indian perspective on the new GATT/WTO agreement. Beginning with a quick sketch of the current global economic scenario, the author explains the details of the individual WTO agreements, including TRIPS. A special chapter is devoted to patents and pharmaceuticals that are the subject of an amendment in India and to the resultant impact on the Indian pharmaceutical sector. The issue of the protection to be granted to plant varieties and microorganisms is also discussed.

This publication analyses the impact of the various WTO agreements and the WTO system on developing countries, with a special focus on India. A chapter is devoted to the TRIPS Agreement. It relates the history of the difficult negotiations leading up to the signing of the Agreement, and discusses the negative effects of the Agreement for developing countries in terms of development, technological dependence and losses. Finally, the author insists on the various possibilities for making the obligations under the Agreement more flexible.


In this trade dispute between the United States and Thailand, the GATT ruled against the Thai efforts to ban imports of cigarettes when there was no equivalent measure taken against the sale of domestically produced cigarettes. However, this case is important for WHO's action in defending public health interests for two reasons. First, the GATT established a precedent in consulting WHO on a trade issue involving public health. Second, the GATT indicated that a ban on the advertising of cigarettes, while potentially harmful to the interests of importers who were not well known, was justified for public health reasons.


The author reviews the TRIPS patent provisions and considers arguments for and against requiring less developed countries to implement Western levels of patent protection. She then addresses the particular example of pharmaceutical protection in India, by reviewing the country's current patent law and discussing the likely effect of TRIPS on the Indian pharmaceutical industry and the Indian population. The article concludes that "there are justifiable fears that patent protection will do more harm than good in developing countries".


This publication is a product of desk research and creative interaction with entrepreneurs, executives, scientists and doctors. It firstly presents the changing international environment with regard to the economic role of pharmaceuticals. It then introduces the public health scenario in India and the drug industry. The last part of the book focuses on the issue of GATT, patents and drugs, comparing the Indian Patent Act with other intellectual property instruments, and discussing the cost of new drugs and how to do without newer drugs.

This article concentrates on the pharmaceutical industry’s prospects with regard to China. The author explains why many international pharmaceutical companies are focusing their interest on China as one of the major pharmaceutical markets in Asia. Pharmaceutical patent protection is described as well as the place of over-the-counter drugs, quality and drug lists, pricing, the strategy of pharmaceutical investment through joint ventures and the local pharmaceutical industry.


Concern over the impact of the Final Act of the Uruguay Round on India’s sovereignty, democracy and the Constitution led to the creation in 1993 of a non-official judges’ panel, entitled the People’s Commission on GATT, to examine the constitutional implications of the Final Act. The report of the People’s Commission begins with a detailed chronology of events which provide a basis for understanding the domestic and international context in which the Final Act was negotiated. A background is provided on the functioning of the previous GATT and the numerous rounds of negotiations preceding the Uruguay Round. The report describes the Indian Government’s handling of the Uruguay Round and then examines the critical sections of the Final Act and their implications for the political economy. An annex reproduces the text of a paper on the Indian view of the future TRIPS Agreement presented at a meeting of a negotiating committee under the Uruguay Round (1989).


The impending change in the patent regime will force Indian industry as well as R&D laboratories to move away from the path of reverse engineering. The author analyses changes with regard to the patenting of microorganisms and the protection of plant varieties. Emerging challenges and opportunities for R&D institutions and industry are investigated, as well as ways to enhance patenting skills in India.


Since the TRIPS Agreement does not provide for the retrospective patenting of drugs already on the market somewhere in the world, no significant effect can be anticipated until after 2005 because the number of patented drugs on the Indian market will be too small for economic impact. Moreover, balances such as government price control should be considered as a safeguard against price explosion. But Indian firms will be affected to a large extent: the focus of R&D
should change into innovation of new processes, development of generic drugs, production of patented drugs under licence and marketing of imported drugs.


According to the author, much of what has been said about the implications of India's commitment to provide patent protection for drugs, and particularly regarding pharmaceutical prices, "has been alarmist and has created needless anxiety". This article sets out therefore to provide a dispassionate examination of the facts. It indicates that any effect on prices will be very gradual and modest. Also, the author suggests that this issue be considered in the context of policies aimed at the better availability of drugs to treat diseases prevalent in India.


The main concern expressed in India about the extension of product patents to pharmaceuticals relates to the increase in drug prices, limited local manufacturing, limited access to new technology and inhibited R&D. In this article, the author suggests that the adverse effect on the growth of the pharmaceutical industry can be reduced if the pharmaceutical industry, the medical profession and the policy-makers rise to the occasion and give a new direction to the drug industry regarding research, drug production and utilization.


The objective of this study is to examine an issue common to several developing countries, but specifically in relation to the situation in India. Part one of this book relates the rise of the Indian pharmaceutical industry and the decline of multinationals in India as a result of the Patent Act of 1970, and the dispute over pharmaceutical patent protection which led to the signing of the TRIPS Agreement. Part two analyses the facts, myths and expectations relating to the implementation of the TRIPS Agreement in India: the speed and depth of patents' penetration of India's drug market, the effects on prices, and the expectations for R&D of new products. The last part explores possible future options for Indian pharmaceutical companies, the Indian Government and research-based multinational drug companies.


This book discusses the possible impact of the new WTO agreements on developing countries. With regard to the TRIPS Agreement, it focuses on patents for pharmaceutical and biotechnology products and their economic impact in respect of innovative capacity, foreign investment, technology transfer and
domestic prices. The author also assesses the particular implications in India for pharmaceutical prices and the Indian drug industry, the impact on microbiology, and the significance for plant varieties.


The patent system in the Republic of Korea has been integrated with international patenting since 1986. Therefore, the author investigates the number of pharmaceutical patents in the Republic of Korea, who files patent applications in that country and what types of invention dominate. In addition, he indicates how non-Republic of Korea companies protect their inventions and to what extent the PCT route is being used.


This chapter discusses some important and special issues which require careful consideration while formulating amendments to the Indian Patent Act, and suggests how to frame a national policy on IP for taking advantage of the post-GATT era. The author focuses on the protection of pure compounds, the patenting of microorganisms and the protection of new plant varieties. He also insists on incentives for innovation and modernization of IPRs offices, including training of adequate IP professionals, creation of a good infrastructure and establishment of a patent tribunal.


This article describes the performance of the Indian pharmaceutical industry. It demonstrates that although comprehensively shielded from foreign competition for two decades by high tariffs, restrictions on drug multinationals, price controls and little or no patent protection, the industry is among the most fiercely competitive in the world. Low purchasing power, together with stiff competition among multiple producers for the same drug, has made Indian drugs among the cheapest in the world. However, future growth will have to combine a global presence with innovative research. If Indian companies have historically relied on export of bulk drugs and on developing countries, they may have to move further to developed countries and to formulations. According to the author, Indian companies could well aspire to international leadership in the manufacture and global marketing of bulk drugs for generics.


India actively debated the enactment of a new patent law to comply with its obligations under the TRIPS Agreement. This debate reflected the ambivalence existing in India to modifying a patent regime that has served the Indian
pharmaceutical industry well since 1970. This sector has developed without
benefit of product patent protection, and delivered drugs at affordable prices.
According to the author, a new patent law in compliance with TRIPS may create
uncertainties and some disruption to a status quo that Indians believe is working
to their advantage.

Watal J. Introducing product patents in the Indian pharmaceutical sector: implications

The issue of prices of pharmaceuticals is very controversial in India. The present
study, using a different methodology compared with previous studies, attempts
to estimate the quantum of price rise if currently patentable drugs were to
receive patent protection in India, and calculate welfare losses with such
protection. It concludes that no more than 10% of the total pharmaceutical
market is likely to be affected, and that the price increase will range between 0
and 64%.

WHO/SEARO. The Uruguay Round and health. The agreement of the World Trade
Organization: a review of its impact on health in countries of the South-East Asia
region. New Delhi, WHO Regional Office for South-East Asia, 1996.

This document is intended to serve as a brief for health ministries in the region
which may help them identify measures necessary to deal with the impact of the
WTO Agreements. It is an attempt to review both the possible impact of the
Agreements and WHO’s efforts to protect health in an environment of trade
liberalization.

WHO/SEARO. TRIPS and the health sector in the South-East Asia region. New Delhi,
WHO Regional Office for South-East Asia, September 1998.

The TRIPS Agreement has serious implications for the health sector in the
countries of the South-East Asia region. WHO/SEARO has a vital role to play in
helping Member States to understand the provisions of this Agreement. This
paper outlines the salient features of the TRIPS Agreement and examines the
patent situation in each country of the region. It then assesses the implications of
patenting of pharmaceutical products in Bangladesh, India, Indonesia, Maldives,
Myanmar, Sri Lanka and Thailand, and the changes in national legislation, and
discusses the role of WHO.
2.3 Europe


The disintegration of the former Soviet Union and Yugoslavia resulted in changes in the patent laws of the Newly Independent States. In 1994, most of the new States set up their own patent offices. This article provides an overview of the legal situation in Eastern Europe. It includes a table showing whether the various jurisdictions protect biotechnology, pharmaceutical and chemical inventions.


The paper discusses the effects that the patenting of medicine in Italy has had since the current legislation was passed in 1978. Comments focus on four areas: the influence of patents on prices, the attitude of the national laboratories and the consequences for national production, the effect of monopolistic patents on the capacity for innovation, and the influence of patents on Italy’s balance of trade in pharmaceuticals.


The strategies adopted by the research-based companies in the pharmaceutical industry to hamper generic competition after patent expiry are many and varied. In some cases, they will take the form of further patents with later expiry than the original one protecting the product, but relating for example to formulations or processes. However, the research-based company can also make the most of its original patents, as discussed in this article, which seeks to summarize developments in Europe over recent years in the underlying legal framework affecting the balance between the generic sector and the research-based sector of this industry.


Differences among EU Member States in political, social, economic, legal and regulatory regimes cause differences in pharmaceutical prices, which in turn create opportunities for parallel trade. This article looks at the current state of parallel trade of prescription medicines in the EU, with a particular focus on Spain as a source of parallel exports. It also analyses some policy implications derived from parallel trade. Finally, it develops a simple microeconomic model for assessing the effects of parallel trade.

Parallel trade is not specific to the pharmaceutical industry and happens wherever there are price differentials. It increases the effectiveness of the market and usually benefits the customer. However, to reap these benefits, the markets must be free. In the pharmaceutical industry, markets are not free and different strategies are required to stem the rapid growth in parallel trade within the EU. According to the author, the outlook for parallel trade may seem bright in the short term but too many factors speak against a prosperous future beyond that, the most crucial being pan-European pricing strategies.


The Italian experience of introducing pharmaceutical patent protection recently is particularly interesting because it presages legal changes that are likely to happen in some developing countries in the WTO TRIPS era. This article investigates how Italian producers adapted to the intellectual property regime changes of 1978. In particular, it undertakes a detailed statistical analysis of changes in drug research and development expenditures and patenting. In addition, it supplements that with information on new drug product introductions, foreign direct investment by multinational enterprises and import-export balances.


When Spain modified its law on generics, it introduced an unusual and controversial set of regulations. This article looks at these changes, and provides the opportunity for industry figures to air their views.


This article deals first with the issue of parallel trade in the EU: its link with price regulation, how parallel trade takes place, whether it results in a market correction or distortion, what are the main exporting and importing countries, and those driving parallel trade. It then stresses the importance of the ECJ's pending judgement in Merck v. Primecrown and of Bayer's appeal against the Commission's decision in Adalat.


The ECJ's judgement in Merck v. Primecrown confirmed that patentees cannot exclude from patented territories goods which they or their licensees have sold
in EU Member States where the goods have no patent protection. This article argues that patentees who do not obtain, and maintain, Europe-wide coverage for their entire patent portfolio are faced with a continued choice between selling Europe-wide at close to unpatented prices, and leaving unpatented territories unexploited.

2.4 Latin America

Ahlert IB. New Brazilian industrial property law. The International Review of Industrial Property and Copyright Law (IIC), 1997, 26(5).

After five years of discussions in the National Congress and ratification of the WTO TRIPS Agreement, the new Industrial Property Law was signed in 1996. It includes several innovations in the patent chapter, most of them following present international trends. As a result, the new law mostly favours strong patent protection in Brazil, although a few points still need to be reviewed in order to achieve full harmonization with TRIPS.


In accordance with the transition periods of the TRIPS Agreement, the new minimum standards of protection are being adopted in the various areas of intellectual property in many developing countries at a very different pace. This article describes first the framework for implementation of the TRIPS Agreement and some aspects relating to the incorporation of the Agreement's provisions into national laws. It then discusses interpretation and instrumental problems that have arisen, and some of the problems faced by developing countries in the process of implementation. The main changes introduced in Latin American and Caribbean countries to implement the TRIPS Agreement are then briefly analysed, followed by the main conclusions.


Argentina belonged to the group of developing countries that did not recognize IPRs in the pharmaceutical field. Although this situation gave rise to a major legal controversy, from the economic point of view it has provided scarce elements for analysis. The need for a critical revision of the legislation became evident, as Argentina would have to adopt a position regarding relevant international changes and the Uruguay Round. This paper aims to point out the issues that will allow for an impartial weighting of the effects caused by the policy of not recognizing pharmaceutical patents, and to make a contribution to evaluating the economic effects deriving from the adoption of alternative systems.

This article develops the essential points of the reform of the Brazilian law on patents, following international pressures: patent protection of microorganisms, chemical and pharmaceutical products, pipeline protection, exhaustion of rights and regulation of compulsory licences.


This is an analysis of the reform of the Brazilian patent law: extension of the domain of patentability, duration of protection, compulsory licences, local working of the patent, and registration of applications for patents on new materials.


After having been in and out of the limelight for five years, Brazil’s new patent law has been approved. This paper focuses on the major changes brought about by the new law as regards patentability and pipeline, biotechnology, state of the art, cost reduction of priority claim, filing and examination of application, term of a patent, compulsory licences and working requirements, restrictions on the rights of the patentee, etc.


Although the new Brazilian law came into force on 15 May 1997, some issues are still controversial and will need to be clarified by the courts, such as the question of patent term extension for pending Brazilian patent applications and existing patents, and the use of the pipeline provisions.


This paper focuses on the present trend towards harmonizing national patent protection with legislation in developed countries, in particular that which deals with the question of the patentability of pharmaceutical processes and products. It presents the Brazilian legislation prior to the signing of the TRIPS Agreement, and the debate on drugs patentability in Brazil.


As a strong emerging market for pharmaceuticals and a leader in Latin America’s science and technology, Brazil is a signatory of the WTO Agreement, including the TRIPS Agreement, and was consequently committed to
introducing pharmaceutical patent protection. According to the author, this book is based on interviews with all shades of opinion on the subject in Brazil, with an extensive study of relevant published sources. It examines the conflict of attitudes over pharmaceutical patent protection in Brazil and considers the prospects. In addition, it evaluates the consequences of eventual patent legislation for the national and multinational drug industry, pharmaceutical chemicals and the trade balance, the pharmaceutical market in Brazil, drug prices and the cost to health care, and finally R&D in pharmaceuticals and biotechnology.


The author considers the complex evolution of the regime of invention patents and utility models in Argentina. After having pointed out the main principles governing the TRIPS Agreement, he deals with the most controversial aspects of the new Argentine regime, such as the transitional period for pharmaceutical patents, the filing of revalidation patents, the term of protection, the compulsory licensing regime and the enforcement of IPRs. Having identified the ambiguous and controversial aspects of these provisions, the author ends by emphasizing the need for their improvement, so that they respect both the Constitution and the international treaties in force.

SELA/IDB. The TRIPS Agreement and international trade: effects on Latin America and the Caribbean. Workshop on the application of the TRIPS Agreement, Mexico City, 20-24 May 1994.

In the context of the Summit of the Americas, the Uruguay Round and NAFTA, intellectual property is one of the issues proposed for discussion. This document is a contribution to the initial stage of dealing with the issue. It first examines the relationship between trade and intellectual property, and the relevance of IP as a factor which can help or hinder legitimate trade. It then analyses data about the extent to which international trade is affected by IP. It describes the general characteristics of the TRIPS Agreement and examines some particular issues such as trade in counterfeit goods, parallel imports, the control of abuses of IPRs and the transfer of technology. Finally, it overviews the consequences of the TRIPS Agreement in Latin America and the Caribbean with the resulting amendments to legislation, and the regional agreements on intellectual property.


Proposals to introduce pharmaceutical patents in Argentina have rekindled the debate between national and multinational companies over the benefits of intellectual property protection in developing countries. The pricing issue is particularly contentious since both sides tend to gather data most favourable to their own viewpoint. Likewise, the true benefits and/or disadvantages of compulsory licensing may be permanently lost in a fog of partisan wrangling. This article explores the stubborn divisions between the two camps.

This article first analyses the objective and rationale of the patent system and the social importance of patents. It then discusses the new Argentine patent law, international trends in IP protection and the hierarchy between national laws and international treaties.


This article examines the question of the relationship between the patent system and competition, the economic perspective, and the benefits of patents in stimulating competition and economic development.

2.5 Middle East

Abouelenein AA. Trade-related aspects of intellectual property rights (TRIPS) and the pharmaceutical industry in Egypt. Cairo, Federation of Egyptian Industry, June 1996.

This publication presents the view of a member of the Board of the Association of Egyptian Industries on the negative effects of the TRIPS Agreement on the country’s pharmaceutical industry. These negative effects not only apply to the national pharmaceutical industry but also extend to economic, social and health aspects in the country.


This paper briefly relates the development of international trade until the WTO was created, with emphasis on the developing countries, and presents the TRIPS Agreement provisions related to pharmaceuticals. It then examines the Arab pharmaceutical industry, pointing out common features such as patent protection for pharmaceutical processes, but also the different pharmaceutical policy orientations. The author concludes that the reorientation of the Arab industry, by joining the WTO, may have a negative effect on public health concerning medicines.

Ghorab MG. Agreement on intellectual property and pharmaceuticals in Egypt. Egypt, 1996 (unpublished paper).

This is a brief presentation of the current drug situation in Egypt followed by an outline of the measures which should accompany the implementation of the TRIPS Agreement, particularly policies on registration and pricing, support to R&D activities and creating strategic alliances. There is also analysis of the advantages accruing from patent protection for the pharmaceutical industry and the Egyptian economy, as well as a discussion on the truths and falsehoods in the drug patents debate.

This publication presents the view of a multinational's subsidiary on the TRIPS Agreement and the dispute over pharmaceutical patent protection. It first presents the views of the major protagonists: the Government, the national companies and the multinationals. It then discusses the issues of speed and depth of patent penetration of the Egyptian market, "check and balances" as regards price explosion and pharmaceutical R&D. Finally, the paper defends the motives for strengthening IP protection and the options that will shape the end game.

2.6 North America

Congressional Budget Office (CBO). How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Available from: URL: http://www.cbo.gov/showdoc.html

In 1984, the United States Drug Price Competition and Patent Term Restoration Act (also known as the Hatch-Waxman Act) created an abbreviated approval process for generic drugs and at the same time extended patent terms for innovator drugs. This study examines the price competition among manufacturers in the pharmaceutical market, including the impact of the dramatic growth in the generic drug industry since 1984. Such competition comes in three main forms: between brand-name drugs in the same therapeutic class, between brand-name drugs and their generic counterparts, and between different generic versions of the same drugs. This study also analyses the changes in patent protection for brand-name drugs as well as supply-side factors that have boosted generic market share, in order to assess how that competition has affected the returns from developing a drug.


This document provides information on the objective and content of Bill C-91, the Patented Medicine Prices Review Board (PMPRB), drug prices/expenditures, Pharmaceutical Manufacturers Association of Canada commitments, and international obligations and comparison, as well as a profile of the Canadian pharmaceutical industry.


All governments face the dilemma of balancing a dual role of encouraging the pharmaceutical industry while at the same time attempting to contain the costs of pharmaceutical products. This paper analyses the trade-off between health policy and industrial policy objectives in the Canadian policy setting. It provides a brief overview of the Canadian health system and the domestic pharmaceutical industry. It examines pharmaceutical policies at the federal and provincial level, and discusses the impact of federal health and industrial policies on the provincial objectives for pharmaceutical cost control.

Since the previous Government passed the controversial Bill C-91, the Canadian generics industry has been campaigning for the repeal of at least some of its provisions, such as the link between a drug’s notice of compliance and its patent status. However, the current Government’s revisions have not lived up to the industry’s expectations.


Canada had always stood out for its special policy in relation to pharmaceutical patents until important changes took place at international level with the negotiation of NAFTA and the WTO TRIPS Agreement. Compulsory licences were at the centre of all these debates and they have attracted attention in Europe. This article investigates what pattern is to be found in all these developments and what are the advantages and disadvantages of the various regimes. It seeks to demonstrate that the new system, while perfectly acceptable in principle, can be improved on a series of points, and that experience under European law can be of assistance.


Pharmaceutical patent litigation in Canada is a burgeoning field. Since 1993, when compulsory licences as of right were abolished and the Patented Medicines (Notice of Compliance) Regulations were enacted, the opportunities for pharmaceutical patentees to enforce their rights have dramatically improved. As a result, a number of legal proceedings have been started by pharmaceutical patentees since 1993, including actions for patent infringement and court applications pursuant to NOC regulations.
3. Electronic information

3.1 Some useful web sites

http://www.cptech.org/ip/health/

The Consumer Project on Technology is active on a number of issues, including intellectual property, telecommunications, privacy and electronic commerce, plus a variety of projects relating to antitrust enforcement and policy. It is also very active in a number of projects involving health care, particularly pricing of intellectual property that relates to medical inventions, and compulsory licensing of essential medical technologies in developing countries. This web site is an extensive source of information providing articles and data on the regional trade agreements and TRIPS, patents and drugs, compulsory licensing, parallel imports, health registration data, generic competition and more.

http://www.southcentre.org/

The South Centre is an intergovernmental body with 46 developing country members. The Centre, however, works for the benefit of the South as a whole, making efforts to ensure that all developing countries and interested groups and individuals have access to its publications and the results of its work, irrespective of membership. The web site provides interesting bibliographical references and papers.

http://www.twinside.org.sg/

The Third World Network is an independent non-profit international network of organizations and individuals involved in issues relating to development, the Third World and North-South issues. The TWN web site offers articles and position papers on a variety of issues related to developing countries, including trade issues and WTO, health, biotechnology and biosafety.

http://www.wipo.org/eng/main.htm

The World Intellectual Property Organization provides basic fundamental information related to intellectual property and patents in general, and to international intellectual property treaties managed by WIPO.

http://www.wto.org/wto/intellec/intellec.htm

The World Trade Organization has a very comprehensive web site and its page on the TRIPS Agreement may be a useful tool.
3.2 Interesting discussion groups

The issue of the impact of international trade agreements on access to drugs and the pharmaceutical sector is increasingly debated through two electronic discussion groups.

http://www.healthnet.org/programs/edrug.html

E-Drug is an electronic conference on essential drugs. E-Drug is used by professionals in this field to obtain and discuss current information on essential drugs, including international and national policies, and standard treatment guidelines.

http://www.hivnet.ch:8000/topics/treatment-access/

Treatment-Access is an electronic discussion forum created and managed by the Fondation du Présent, a non-profit NGO, which brings together a multisectoral community of more than 12,000 members – half of them in developing countries – to raise and jointly resolve AIDS related issues through email discussion.

***
Other documents in the EDM
Health Economics and Drugs Series

No. 1 Alternative drug pricing policies in the Americas
No. 2 The public and private circuits for the distribution of drugs in the Chilean health system
No. 3 Global comparative pharmaceutical expenditures (In preparation)
No. 4 Financing drugs in South-East Asia. Report of the first meeting of the WHO/SEARO Working Group on Drug Financing
No. 5 Public-private roles in the pharmaceutical sector. Implications for equitable access and rational drug use
No. 6 Health reform and drug financing. Selected topics
No. 7 Globalization and access to drugs. Perspectives on the WTO/TRIPS Agreement
No. 8 Financing drugs in South-East Asia. Report of the second meeting of the WHO/SEARO Working Group on Drug Financing
The WHO Department of Essential Drugs and Medicines Policy (EDM) seeks to ensure that all people, wherever they may be, are able to obtain the drugs they need at a price that they and their country can afford; that these drugs are safe, effective and of good quality; and that they are prescribed and used rationally. It provides operational support to countries in the development and implementation of national drug policies based on the concept of essential drugs and it promotes the rational use of drugs at every level.

Health economics is of increasing relevance in the formulation and development of national drug policies that promote equity and rationalize the use of community and state resources. In many countries the new economic context and the global increase in pharmaceutical prices has highlighted the socio-economic aspects of drug use and accessibility. In this process, national drug policies have evolved from a primarily technical and pharmacological focus to encompass social and economic dimensions.

The Health Economics Series provides an orientation and an analysis of key issues. It aims to provide drug policy makers, planners and managers with the information and practical tools needed for policy development within this wider context.